

| Press Release |

Recobia Therapeutics wants to maximize access to cutting edge cancer treatments by altering the administration route

Strasbourg, France – March 28, 2024 – Recobia Therapeutics, a biotechnology-based startup in Strasbourg, has developed a groundbreaking solution for subcutaneous administration of biotherapies more and more adopted as a cancer treatment. This start-up is disrupting a highly dynamic market by replacing patients' quality of life at the core of its development. Their innovative technology, along with its substantiated proof of concept, has been featured in the esteemed scientific journal *Advanced Materials* in December 2023, thereby achieving another milestone.


With its first product, “RecoGel”, Recobia Therapeutics makes it possible to deliver monoclonal antibodies used in cancer therapies through a subcutaneous injection instead of the classical and commonly used intravenous route. This approach not only improves patients' quality of life and mobility but also impacts significantly medical resources invested. With a reduced discomfort and quicker administration, potentially reducing hospital stays and minimizing infection occurrence, patients' experience of their oncological treatment is improving, whilst the medical care environment is saving precious resources at the same time.

Professor Alexandre Detappe, head of the nanotranslational research laboratory at the Institute of Cancerology of Strasbourg Europe (ICANS) and co-founder of Recobia Therapeutics, quotes: "RecoGel opens up exciting new clinical possibilities, including a potential long-term management of patients at home, significantly improving treatment adherence and liberating medical resources at the same time."

The efficacy of RecoGel was validated through a preclinical study done on breast cancer, published in *Advanced Materials* in December 2023. In addition, the RecoGel platform is explored for application in other oncology biologic therapies in a robust pipeline, supporting the company's vision and ambition.

About Recobia Therapeutics

Recobia Therapeutics has been founded in 2022 in collaboration with ICANS, as a preclinical-stage biotechnology-based startup in Strasbourg. The founding team is



constituted of renowned experts in oncology and nanotechnology—Prof. Xavier Pivot, Prof. Alexandre Detappe, Prof. Olivier Tillement, and Dr. Lotfi Boudali. The company is pioneering a patented delivery platform for subcutaneous administration of high-dose monoclonal antibodies in oncology and hematology. Recobia Therapeutics wants to facilitate treatment access for oncology patients by transitioning biotherapies from intravenous to subcutaneous administration. The company has received support from SEMIA and Quest for Health and secured financing from the Grand Est Region and Bpifrance.

Contacts

Coralie GRANGE
Chief Operating Officer
c.grange@recobiatx.com
Tél : 0388252484

Alexandre DETAPPE
Chief Scientific Officer
a.detappe@recobiatx.com
Tél : 0783026392

Recobia Therapeutics SAS
3 rue de la porte de l'Hopital
67000 Strasbourg, France
media@recobiatx.com
<https://recobiatx.com/>